FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095256598> ?p ?o ?g. }

• W2095256598 endingPage "2473" @default.
• W2095256598 startingPage "2473" @default.
• W2095256598 abstract "Type 1 diabetes usually has a preclinical phase identified by circulating islet autoantibodies, but the rate of progression to diabetes after seroconversion to islet autoantibodies is uncertain.To determine the rate of progression to diabetes after islet autoantibody seroconversion.Data were pooled from prospective cohort studies performed in Colorado (recruitment, 1993-2006), Finland (recruitment, 1994-2009), and Germany (recruitment, 1989-2006) examining children genetically at risk for type 1 diabetes for the development of insulin autoantibodies, glutamic acid decarboxylase 65 (GAD65) autoantibodies, insulinoma antigen 2 (IA2) autoantibodies, and diabetes. Participants were all children recruited and followed up in the 3 studies (Colorado, 1962; Finland, 8597; Germany, 2818). Follow-up assessment in each study was concluded by July 2012.The primary analysis was the diagnosis of type 1 diabetes in children with 2 or more autoantibodies. The secondary analysis was the diagnosis of type 1 diabetes in children with 1 autoantibody or no autoantibodies.Progression to type 1 diabetes at 10-year follow-up after islet autoantibody seroconversion in 585 children with multiple islet autoantibodies was 69.7% (95% CI, 65.1%-74.3%), and in 474 children with a single islet autoantibody was 14.5% (95% CI, 10.3%-18.7%). Risk of diabetes in children who had no islet autoantibodies was 0.4% (95% CI, 0.2%-0.6%) by the age of 15 years. Progression to type 1 diabetes in the children with multiple islet autoantibodies was faster for children who had islet autoantibody seroconversion younger than age 3 years (hazard ratio [HR], 1.65 [95% CI, 1.30-2.09; P < .001]; 10-year risk, 74.9% [95% CI, 69.7%-80.1%]) vs children 3 years or older (60.9% [95% CI, 51.5%-70.3%]); for children with the human leukocyte antigen (HLA) genotype DR3/DR4-DQ8 (HR, 1.35 [95% CI, 1.09-1.68; P = .007]; 10-year risk, 76.6% [95% CI, 69.2%-84%]) vs other HLA genotypes (66.2% [95% CI, 60.2%-72.2%]); and for girls (HR, 1.28 [95% CI, 1.04-1.58; P = .02];10-year risk, 74.8% [95% CI, 68.0%-81.6%]) vs boys (65.7% [95% CI, 59.3%-72.1%]).The majority of children at risk of type 1 diabetes who had multiple islet autoantibody seroconversion progressed to diabetes over the next 15 years. Future prevention studies should focus on this high-risk population." @default.
• W2095256598 created "2016-06-24" @default.
• W2095256598 creator A5000141478 @default.
• W2095256598 creator A5001640598 @default.
• W2095256598 creator A5006967177 @default.
• W2095256598 creator A5024635734 @default.
• W2095256598 creator A5026837875 @default.
• W2095256598 creator A5038398583 @default.
• W2095256598 creator A5040673213 @default.
• W2095256598 creator A5058889710 @default.
• W2095256598 creator A5066618511 @default.
• W2095256598 creator A5082377056 @default.
• W2095256598 creator A5088970962 @default.
• W2095256598 creator A5089367639 @default.
• W2095256598 date "2013-06-19" @default.
• W2095256598 modified "2023-10-14" @default.
• W2095256598 title "Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children" @default.
• W2095256598 cites W1933121275 @default.
• W2095256598 cites W1978599215 @default.
• W2095256598 cites W2013359164 @default.
• W2095256598 cites W2026309937 @default.
• W2095256598 cites W2026889435 @default.
• W2095256598 cites W2034559534 @default.
• W2095256598 cites W2052388580 @default.
• W2095256598 cites W2055463878 @default.
• W2095256598 cites W2057159752 @default.
• W2095256598 cites W2071666782 @default.
• W2095256598 cites W2077565597 @default.
• W2095256598 cites W2088364920 @default.
• W2095256598 cites W2093326004 @default.
• W2095256598 cites W2097649243 @default.
• W2095256598 cites W2123412381 @default.
• W2095256598 cites W2136015010 @default.
• W2095256598 cites W2139394184 @default.
• W2095256598 cites W2140028073 @default.
• W2095256598 cites W2140973227 @default.
• W2095256598 cites W2142287176 @default.
• W2095256598 cites W2143958400 @default.
• W2095256598 cites W2157440365 @default.
• W2095256598 cites W2164736991 @default.
• W2095256598 cites W2166782145 @default.
• W2095256598 cites W2326904657 @default.
• W2095256598 cites W403860537 @default.
• W2095256598 cites W614574849 @default.
• W2095256598 doi "https://doi.org/10.1001/jama.2013.6285" @default.
• W2095256598 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4878912" @default.
• W2095256598 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23780460" @default.
• W2095256598 hasPublicationYear "2013" @default.
• W2095256598 type Work @default.
• W2095256598 sameAs 2095256598 @default.
• W2095256598 citedByCount "870" @default.
• W2095256598 countsByYear W20952565982013 @default.
• W2095256598 countsByYear W20952565982014 @default.
• W2095256598 countsByYear W20952565982015 @default.
• W2095256598 countsByYear W20952565982016 @default.
• W2095256598 countsByYear W20952565982017 @default.
• W2095256598 countsByYear W20952565982018 @default.
• W2095256598 countsByYear W20952565982019 @default.
• W2095256598 countsByYear W20952565982020 @default.
• W2095256598 countsByYear W20952565982021 @default.
• W2095256598 countsByYear W20952565982022 @default.
• W2095256598 countsByYear W20952565982023 @default.
• W2095256598 crossrefType "journal-article" @default.
• W2095256598 hasAuthorship W2095256598A5000141478 @default.
• W2095256598 hasAuthorship W2095256598A5001640598 @default.
• W2095256598 hasAuthorship W2095256598A5006967177 @default.
• W2095256598 hasAuthorship W2095256598A5024635734 @default.
• W2095256598 hasAuthorship W2095256598A5026837875 @default.
• W2095256598 hasAuthorship W2095256598A5038398583 @default.
• W2095256598 hasAuthorship W2095256598A5040673213 @default.
• W2095256598 hasAuthorship W2095256598A5058889710 @default.
• W2095256598 hasAuthorship W2095256598A5066618511 @default.
• W2095256598 hasAuthorship W2095256598A5082377056 @default.
• W2095256598 hasAuthorship W2095256598A5088970962 @default.
• W2095256598 hasAuthorship W2095256598A5089367639 @default.
• W2095256598 hasBestOaLocation W20952565982 @default.
• W2095256598 hasConcept C126322002 @default.
• W2095256598 hasConcept C134018914 @default.
• W2095256598 hasConcept C159654299 @default.
• W2095256598 hasConcept C163764329 @default.
• W2095256598 hasConcept C165220095 @default.
• W2095256598 hasConcept C181199279 @default.
• W2095256598 hasConcept C185592680 @default.
• W2095256598 hasConcept C203014093 @default.
• W2095256598 hasConcept C2777180221 @default.
• W2095256598 hasConcept C2777451964 @default.
• W2095256598 hasConcept C2779306644 @default.
• W2095256598 hasConcept C2781232474 @default.
• W2095256598 hasConcept C55493867 @default.
• W2095256598 hasConcept C555293320 @default.
• W2095256598 hasConcept C71924100 @default.
• W2095256598 hasConcept C9497952 @default.
• W2095256598 hasConceptScore W2095256598C126322002 @default.
• W2095256598 hasConceptScore W2095256598C134018914 @default.
• W2095256598 hasConceptScore W2095256598C159654299 @default.
• W2095256598 hasConceptScore W2095256598C163764329 @default.
• W2095256598 hasConceptScore W2095256598C165220095 @default.
• W2095256598 hasConceptScore W2095256598C181199279 @default.

• next